LZTR1 and Miyoshi myopathy: These screens and follow-up experiments reveal unique biology governing oncogenic RAS signaling specific to MM and other hematologic cancers, centered on the phosphorylation-dependent, LZTR1-mediated degradation of mutant RAS isoforms.